• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Botox (onabotulinumtoxinA)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Botox (onabotulinumtoxinA)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Botox blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. Acetylcholine is a neurotransmitter at somatic neuromuscular junctions, the parasympathetic nervous system, sympathetic preganglionic fibers (cholinergic fibers), and at some synapses in the central nervous system.

    Botox for injection is specifically indicated for the prophylaxis of headaches in adult patients with chronic migraine (more than 15 days per month with headache lasting 4 hours a day or longer).

    Botox is supplied as a solution for intramuscular injection. The recommended initial dose is 155 Units administered intramuscularly (IM) using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections should be divided across 7 specific head/neck muscle areas: Frontalis, Corrugator, Procerus, Occipitalis, Temporalis, Trapezius, Cervical Paraspinal Muscle Group. With the exception of the procerus muscle, which should be injected at 1 site (midline), all muscles should be injected bilaterally with half the number of injection sites administered to the left, and half to the right side of the head and neck. The recommended retreatment schedule is every 12 weeks.

    Clinical Results

    FDA Approval
    The FDA approval of Botox for chronic migraine was based on two randomized, multi-center, 24-week, 2 injection cycle, placebo-controlled double-blind studies. Both studies included chronic migraine adults who were not using any concurrent headache prophylaxis, and during a 28-day baseline period had at least 15 headache days lasting 4 hours or more, with at least 50% of these being migraine/probable migraine. In both studies, patients were randomized to receive placebo or 155 Units to 195 Units Botox injections every 12 weeks for the 2-cycle, double-blind phase. At 28 days, the efficacy data are as follows:
    Study One
    Change from baseline in frequency of headache days: -7.8 for Botox vs. -6.4 for placebo (p≤0.05).
    Change from baseline in total cumulative hours of headache on headache days: -107 for Botox vs. -70 for placebo (p≤0.05).
    Study Two
    Change from baseline in frequency of headache days: -9.2 for Botox vs. -6.9 for placebo (p≤0.05).
    Change from baseline in total cumulative hours of headache on headache days: -134 for Botox vs. -95 for placebo (p≤0.05).

    The subjects treated with Botox had a significantly greater mean decrease from baseline in the frequency of headache days at most timepoints from Week 4 to Week 24 in Study 1 and all timepoints from Week 4 to Week 24 in Study 2 compared to placebo-treated patients.

    Side Effects

    Adverse events associated with the use of Botox for migraine may include, but are not limited to, the following:

    • neck pain
    • headache
    • worsening migraine
    • muscular weakness
    • eyelid ptosis

    Mechanism of Action

    Botox blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.

    Literature References

    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF; PREEMPT 2 Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia : an international journal of headache 2010 Jul;30(7):804-14

    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia : an international journal of headache 2010 Jul;30(7):793-803.

    Additional Information

    For additional information regarding Botox or chronic migraine, please visit the Botox web page.

    Approval Date: 2010-10-01
    Company Name: Allergan
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing